Why the study?
Yiqi Huoxue decoction showed potential for myocardial infarction, but its regulation of mitochondria-associated membranes and associated Ca2+ mechanisms remained unclear.
Yiqi Huoxue decoction demonstrates cardioprotective effects in preclinical models of myocardial infarction by regulating calcium homeostasis and preserving mitochondria-associated membranes.
Background Mitochondria-associated membranes (MAMs) regulate cellular Ca 2+ and contribute to cardiovascular disease pathogenesis. The IP3R-GRP75-VDAC1 complex is the primary MAMs pathway regulating Ca 2+ flux and cardiomyocyte calcium homeostasis. Yiqi Huoxue decoction (YQHX), a Traditional Chinese Medicine formula, shows potential for myocardial infarction (MI) prevention and treatment. However, YQHX's regulation of MAMs and associated Ca 2+ mechanisms in MI remains unclear. Methods MI rat and oxygen-glucose deprivation cardiomyocytes model were used to mimic myocardial ischemia in human. in vivo , Rats were randomly divided into Sham, Model, YQHX (8.2 g/kg) and Perindopril (10 mg/kg) groups. 28 days after MI, echocardiography, HE, Masson staining and transmission electron microscopy detections were performed to observe cardiac functions and morphology. The effects of YQHX on H9c2 cell viability, mPTP and Ca 2+ levels were examined in vitro . Proteins located at MAMs including Cyclophilin D (CypD), Mitochondrial Calcium Uniporter (MCU), Sigma-1 Receptor (Sig-1R), and Neurite Outgrowth Inhibitor B (NOGO-B) are abundantly expressed in myocardial tissue. Consequently, these proteins, along with components of the IP3Rs-GRP75-VDAC1 complex, were detected using WB and qPCR. Mitofusin 2 (Mfn2), which regulates mitochondrial function and Ca 2+ flux and is widely expressed at MAMs, was assessed using immunofluorescence.MKT-077, an agent known to disrupt the IP3Rs-GRP75-VDAC1 complex, was employed to investigate the mechanism of YQHX on the complex. Results YQHX improved cardiac function and attenuated pathological changes in vivo . It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro , YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca 2+ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. YQHX also restored MAMs morphology, decreased mPTP opening and Ca 2+ levels, and reversed GRP75 downregulation blocked by MKT-077 under oxygen-glucose deprivation. Conclusions YQHX exerts cardioprotection against hypoxia by regulating Ca 2+ homeostasis and preserving MAMs structure, function, and associated protein expression.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: